Past, Present, and Future of Viral Hepatitis in Bangladesh

ABSTRACT Viral hepatitis poses huge burden to the health care delivery system as well as to the economy of Bangladesh. Hepatitis E virus is the leading cause of acute hepatitis in this country, however with the improvement of economic status and sanitation this seems to be on the decline. Hepatitis B virus remains the leading cause in all forms of chronic liver diseases in this country. This virus has been extensively studied in Bangladesh, including from epidemiology to pathogenosis. Clinical trials with innovative therapy conducted in Bangladesh have shown promise. Hepatitis C virus follows hepatitis B virus as the second commonest cause of chronic liver diseases here. However patients in Bangladesh have started benefitting from the local generic versions of the newly introduced direct acting anti-virals. How to cite this article Al-Mahtab M. Past, Present, and Future of Viral Hepatitis in Bangladesh. Euroasian J Hepato-Gastroenterol 2016;6(1):43-44.

the fact that we enjoy local, generics for anti-HBV drugs, i.e., tenofovir, entecavir, adefovir, lamivudine, and pegylated interferon (Peg IFN), with the exception of only telbivudine. However, as we more often see HBeAgnegative HBV infection in Bangladesh with the principal HBV genotype (GT) being GT C, the management of HBV remains a challenge for us.
Groundbreaking research is being conducted in Bangladesh for the development of new drugs against HBV, which include phase I/II and subsequent phase III studies with a therapeutic vaccine called NASVAC, comprising HBsAg and HBcAg and another nucleic acid polymer called Rep 09C that inhibits HBsAg release from infected hepatocytes. NASVAC, in particular, needs special mention, as it is the only immune therapy not only for HBV but for any chronic infection that has successfully gone through a phase III clinical trial; this has established its superiority over Peg IFN, 6 prompting much enthusiasm globally as well as multicenter European and Asia Pacific clinical trials. Both drugs are expected in the market before the turn of the current decade.

HEPATITIS C VIRUS
There is limited data about the prevalence of hepatitis C virus (HCV) in Bangladesh. Most of the studies are also carried out in limited population. Published literature puts the figures to anything between 0.2% and approximately 1% in the general population. The same applies for Bangladeshi immigrants to Europe, as studies have reported that the prevalence of HCV among Bangladeshi immigrants in Spain and UK is 0.09 and 0.6% respectively. The figures, as expected, are much higher among high-risk population, being as high as 24.8% among intravenous drug abusers. However, it is generally accepted that the prevalence HCV in this country is 0.84%. 7,8 As with HBV, principal risk factors for the transmission of HCV in Bangladesh have also been identified as treatment from quacks, shaving and haircut in barber shops, body piercing, as well as vaccination against small pox, cholera, dental procedure, intravenous infusion, etc. 7 There is a male predominance with males accounting for more than 70% HCV infections. More than 60% HCV-infected people in Bangladesh are between 30 and 50 years of age, and HCV is the second leading cause of CLD in Bangladesh, next only to HBV, accounting for 30% cases of liver cirrhosis and 17% cases of HCC. However, in recent times, we are experiencing a rise in fatty liver disease, which may bypass HCV in the next decade as the second leading cause of CLD.
The predominant GT of HCV in Bangladesh is GT 3 (50-89%), followed by GT 1 (8-29%). 9 Until 2015, the mainstay of treatment of HCV in Bangladesh was double therapy consisting of Peg IFN and ribavirin (RIBA), with a reported SVR of 80% in GT 3. However, things have changed dramatically since February 2015, with the introduction of local, generic sofosbuvir (SOF) in our markets. We now also have local generic daclatasvir (DAC) and ladipasvir (LPV), in addition to generic Peg IFN and RIBA. This has opened a whole new spectrum of affordable treatment for HCV for Bangladeshi patients, which has been facilitated by a favorable government policy of withdrawal of tax and VAT on anti-HCV drugs. The cost of DAC in Bangladesh is less than USD 1.0, no wonder why we are seeing a sudden influx of health tourism in Bangladesh not only from the region but also from Europe and USA. Initial data from Bangladesh with triple therapy consisting of Peg IFN, SOF, and RIBA are showing promising results comparable with the published literature. 10 Studies combining SOF plus DAC, Peg IFN, DAC plus RIBA, and SOF plus LPV are ongoing and data are expected to be released in 2016. However, the eradication of HCV from Bangladesh is still possibly a far cry, as it has been estimated that it will take more than 20 years to reduce the burden of HCV in India by 20%.

HEPATITIS E VIRUS
Being a member of the developing world with significant poverty and poor hygienic conditions, not unexpectedly Bangladesh offers favorable conditions for nurturing hepatitis E virus (HEV) infection. Not only seasonal, but also sporadic, nonseasonal HEV outbreaks with significant mortality have been reported from Bangladesh. 11 Not to mention that HEV remains the leading cause of acute hepatitis and also fatal conditions like acute hepatitis in pregnancy 2 and acute chronic liver failure (ACLF) in this country. 12 However, things are finally possibly moving in the positive direction, following the economic growth that Bangladesh has experienced in the recent years and the resultant improvement of socioeconomic, general living, and hygienic conditions. We are now seeing less cases of HEV during the monsoon in Bangladesh, and interestingly, unlike in 2013, in 2015 acute HBV infection bypassed acute HEV as the leading acute insult in ACLF in the country. 13 It may therefore be predicted with confidence that HEV may become a bygone story in Bangladesh in the next couple of decades.